AU Patent

AU2017210156A1 — Differential diagnosis of Ectopic Cushing's Syndrome

Assigned to Corcept Therapeutics Inc · Expires 2018-09-06 · 8y expired

What this patent protects

Improved methods and systems for differentially diagnosing ACTH-dependent Cushing's syndrome are provided herein. Treatment methods can use glucocorticoid receptor antagonists, which differentially affects the ratio of cortisol to ACTH levels in patients having Cushing's Disease …

USPTO Abstract

Improved methods and systems for differentially diagnosing ACTH-dependent Cushing's syndrome are provided herein. Treatment methods can use glucocorticoid receptor antagonists, which differentially affects the ratio of cortisol to ACTH levels in patients having Cushing's Disease versus patients having Ectopic Cushing's Syndrome. Methods for differentially diagnosing ACTH-dependent Cushing's syndrome can include obtaining baseline cortisol and ACTH levels of a patient, treating the patient with a glucocorticoid receptor antagonist (GRA) according to a protocol that would typically substantially elevate cortisol levels, obtaining post-treatment cortisol and ACTH levels of the patient, determining a differential relationship between baseline cortisol and ACTH levels and post-treatment cortisol and ACTH levels and providing a positive diagnosis based on the differential relationship.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017210156A1
Jurisdiction
AU
Classification
Expires
2018-09-06
Drug substance claim
No
Drug product claim
No
Assignee
Corcept Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.